Moreover, for mice transplanted with MAPK7-KD-A375 cells, compared to PD-1 treatment alone, the combination of PRKDC and a PD-1 inhibitor significantly reduced tumor growth (Fig. 7r), confirming the potential of using a PRKDC inhibitor combined with an anti-PD-1 antibody for melanoma treatment in the future. This evidence concerns the gene PDCD1 and melanoma.